Patents Assigned to Eli Lilly and Company
  • Patent number: 11365185
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutical salt thereof, use, methods for its preparation are described.
    Type: Grant
    Filed: August 28, 2018
    Date of Patent: June 21, 2022
    Assignee: Eli Lilly and Company
    Inventors: Tianwei Ma, Liang Wu, Xuejun Zhang
  • Patent number: 11357820
    Abstract: A composition of tirzepatide, comprising an agent selected from NaCl and propylene glycol; and dibasic sodium phosphate is provided.
    Type: Grant
    Filed: June 14, 2019
    Date of Patent: June 14, 2022
    Assignee: Eli Lilly and Company
    Inventors: Vincent John Corvari, Christopher Sears Minie, Dinesh Shyamdeo Mishra, Ken Kangyi Qian
  • Patent number: 11357923
    Abstract: A sensing system for determining a zero position of a medication delivery device. The sensing system includes at least one actuator member, a biasing member, a stop surface and a sensor. The stop surface is structured and arranged within the device housing for abutment by a push surface of the at least one actuator member as a screw element of the device screws to a zero position from a dosing position. The abutment forces the at least one actuator member to move relative to the screw element from a first position to a second position against a resistance provided by the biasing member. A sensor within an electronics module is adapted to recognize the at least one actuator member at the second position.
    Type: Grant
    Filed: October 6, 2016
    Date of Patent: June 14, 2022
    Assignee: Eli Lilly and Company
    Inventor: Gabriele Ganzitti
  • Patent number: 11351251
    Abstract: The present invention relates to antibodies that are heterodimeric and bind human PD-L1 and human TIM-3, and may be useful for treating cancer alone and in combination with chemotherapy and other cancer therapeutics.
    Type: Grant
    Filed: March 12, 2019
    Date of Patent: June 7, 2022
    Assignees: Eli Lilly and Company, Zymeworks Inc.
    Inventors: Yiwen Li, Dale Lincoln Ludwig, Yang Shen, Yi Zhang, Igor Edmondo Paolo D'Angelo
  • Patent number: 11352424
    Abstract: The present invention relates to antibodies that bind human T-cell immunoglobulin- and mucin-domain-containing protein-3 (Tim-3), and may be useful for treating solid and hematological tumors in combination with anti-human PD-1 antibodies, chemotherapy, and ionizing radiation.
    Type: Grant
    Filed: December 4, 2017
    Date of Patent: June 7, 2022
    Assignees: Eli Lilly and Company, Innovent Biologics (Suzhou) Co. Ltd.
    Inventors: Yiwen Li, Yi Zhang
  • Patent number: 11353436
    Abstract: A centrifugation approach used to accelerate current empirical methods used to investigate silicone drainage in syringes is disclosed. A siliconized syringe is placed into a holder of a centrifuge in a predefined orientation. Centrifugation of the syringe is activated at a predetermined G rate and for a period of intended simulation time and is ended as that time elapses. The time can be a function of intended simulation time, acceleration due to gravity, square of centrifuge revolution rate, and distance from center of rotor hub to matching point on the syringe barrel. One or more injection functionality parameters of the syringe is assessed after the elapsed period of time. A bucket fixture for retaining one or more syringes in the predefined orientation is also disclosed.
    Type: Grant
    Filed: March 26, 2020
    Date of Patent: June 7, 2022
    Assignee: Eli Lilly and Company
    Inventors: Brian Frank Lewis, Bernard Michael McGarvey
  • Patent number: 11344669
    Abstract: A rotary sub-assembly for pumping of fluid is provided. The sub-assembly includes a hollow body defining a cavity having a longitudinal axis, the body comprising a cavity wall with at least two ports passing therethrough. At least a portion of the cavity has a non-circular cross-section such that a first constant or varying radial distance from the longitudinal axis to inwardly-offset segments of the cavity wall surrounding the two ports is less than a second constant or varying radial distance from the longitudinal axis to second segments of the cavity wall spaced apart from the two ports. A rotatable plunger is housed in the cavity. The plunger is sized and shaped such that a side wall of the plunger can establish a liquid-tight seal against the inwardly-offset segments of the cavity wall, but does not establish a liquid-tight seal with the second segments of the cavity wall spaced apart from the two ports.
    Type: Grant
    Filed: August 21, 2020
    Date of Patent: May 31, 2022
    Assignee: Eli Lilly and Company
    Inventors: Ryan Michael Agard, Matthew James Clemente, Shaun Robert Devitt
  • Patent number: 11319370
    Abstract: The present invention relates to anti-human CD200R agonist antibodies, and uses thereof for treating diseases such as atopic dermatitis, chronic spontaneous urticaria, allergy, asthma, scleroderma, IBD, SLE, MS, RA, GvHD, or psoriasis.
    Type: Grant
    Filed: September 11, 2019
    Date of Patent: May 3, 2022
    Assignee: Eli Lilly and Company
    Inventors: Stephen J Demarest, Anja Koester, Scott Charles Potter, Diana Isabel Ruiz, Derrick Ryan Witcher, Xiufeng Wu, Payal Mehta
  • Patent number: 11312763
    Abstract: The invention is directed to a short term induction treatment with anti-N3pGlu A? antibodies of a disease characterized by deposition of A? in the brain, that include Alzheimer's disease (AD), Down's syndrome, and cerebral amyloid angiopathy (CAA). In certain embodiments, patients are administered an induction dose of 10 to 60 mg/kg of an anti-N3pGlu A? antibody for a period of 6 months or less.
    Type: Grant
    Filed: June 23, 2017
    Date of Patent: April 26, 2022
    Assignee: Eli Lilly and Company
    Inventors: Ronald Bradley Demattos, Michael Carl Irizarry
  • Patent number: 11298462
    Abstract: An automatic injection device is provided, where the device includes a syringe carrier and a retraction assembly. The syringe carrier includes two identical parts that are discrete from one another and interlock with one another. The retraction assembly includes a shuttle and a follower, the follower having a moveable latch. The follower has a coupled configuration in which the latch is biasedly coupled to the shuttle, and a decoupled configuration in which the latch is in sliding engagement with a curvilinear surface of the shuttle.
    Type: Grant
    Filed: March 6, 2020
    Date of Patent: April 12, 2022
    Assignee: Eli Lilly and Company
    Inventors: William Godwin Atterbury, Joseph Daniel Dennis, Jr., Brian Charles Kelley, Mark Lafever, Steven Michael Madland, Andrew Thomas Snow, Jessica Diane Young
  • Patent number: 11298362
    Abstract: Medicaments for use in treating acute myelogenous leukemia, chronic myelogenous leukemia, breast cancer, ovarian cancer, malignant melanoma, lung cancer, pancreatic cancer, glioblastoma, sarcoma, desmoid tumors, adenoid cystic carcinoma (ACC), colorectal cancer, prostate cancer, or medulloblastoma in a patient by administering simultaneously, separately, or sequentially, 4,4,4-trifluoro-N-[(IS)-2-[[(7S)-5-(2-hydroxyethyl)-6-oxo-7H-pyrido[2,3-d][3]benzazepin-7-yl]amino]-1-methyl-2-oxo-ethyl]butanamide, or a pharmaceutically acceptable salt or hydrate thereof, and N-[5-(4-ethyl-piperazin-1-ylmethyl)-pyridin-2-yl]-[5-fluoro-4-(7-fluoro-3-isopropyl-2-methyl-3H-benzoimidazol-5-yl)-pyrimidin-2-yl]-amine, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: April 5, 2017
    Date of Patent: April 12, 2022
    Assignee: Eli Lilly and Company
    Inventors: Richard Paul Beckmann, Bharvin Kumar Patel
  • Patent number: 11286249
    Abstract: The present invention provides compounds of the Formula wherein L is selected from the group consisting of —CH2NHCH2—, —CH2NH—, —NH—, —S—, —S(O)—, —S(O)2—, —O—, —OCH2—, —OCH2CH2O—, —NHSO2NH—, or a pharmaceutically acceptable salt thereof; a compound of the formula: processes for preparing the compounds and their salts, a pharmaceutical composition, and methods of treating patients in need of such treatment.
    Type: Grant
    Filed: June 3, 2020
    Date of Patent: March 29, 2022
    Assignee: Eli Lilly and Company
    Inventors: Celia Lafuente Blanco, Nuria Diaz Buezo, Jose Antonio Martinez Perez, Gema Consuelo Sanz Gil, Julian Priego Soler
  • Patent number: 11267882
    Abstract: Provided are antibodies, or an antigen-binding fragment thereof, that binds human IL-21, These antibodies are useful in immunoassays of IL-21 levels, and/or in vivo, ex vivo or in vitro immunochemical and other imaging methods for determining the presence of IL-21 and/or quantifying IL-21 levels, and for diagnostic, prognostic and predictive purpose, and or optimizing therapeutic regimens in patients in which IL-21 signaling is implicated in pathogenesis.
    Type: Grant
    Filed: March 24, 2017
    Date of Patent: March 8, 2022
    Assignee: ELI LILLY AND COMPANY
    Inventors: Stuart Willis Bright, Julian Davies, Andrea Paula Martin, Joshua Dade Poorbaugh, Oliver Schroeder, Karen Leigh Cox, Angus John MacDonald, Xiao-Fen Wang, Sean Edward Sissons
  • Patent number: 11266788
    Abstract: Sensing systems, devices and methods are disclosed for determining the relative movement of first and second members of a medication delivery device which are proportional to the amount of a dose set and/or delivered by operation of the medication delivery device. A sensor is coupled with the first member. A pair of targets is coupled with the second member. Each target comprises an array of teeth which move through an area sensed by the sensor. The sensor thereby detects characteristic values of a sensed parameter corresponding to the combined relative positions of the first and second members. The sensing system outputs this information to a processor which determines the amount of the dose set and/or delivered. Related medication delivery devices and methods are also disclosed.
    Type: Grant
    Filed: April 12, 2017
    Date of Patent: March 8, 2022
    Assignee: Eli Lilly and Company
    Inventors: Roy Howard Byerly, Russell Wayne Perkins
  • Publication number: 20220062265
    Abstract: The present invention relates to dosing regimens and methods of using LY3154207, also described as 2-(2,6-dichlorophenyl)-1-[(1S,3R)-3-(hydroxymethyl)-5-(3-hydroxy-3-methylbutyl)-1-methyl-3,4-dihydroisoquinolin-2(1H)-yl]ethanone, and/or pharmaceutical compositions thereof, for treatment of dopaminergic central nervous system disorders. Dopaminergic CNS disorders of the present dosing regimen methods include Parkinson's Disease, Alzheimer's Disease, Lewy body dementia (LBD), Vascular Dementia, Schizophrenia, ADHD, Depression, Autism, chronic musculoskeletal pain, fibromyalgia, cognitive impairment disorders, sleep disorders, excessive daytime sleepiness, narcolepsy, shift work disorder, traumatic brain injury, chronic traumatic encephalopathy, obesity and appetite regulation, mood disorders, lethargy, apathy, and addiction disorders.
    Type: Application
    Filed: December 16, 2019
    Publication date: March 3, 2022
    Applicant: Eli Lilly and Company
    Inventors: Kevin Michael BIGLAN, Christina Marie KILEY, Kjell Anders Ivan SVENSSON
  • Patent number: 11253574
    Abstract: The present invention relates to fusion proteins comprising an insulin receptor agonist fused to a human IgG Fc region through the use of a peptide linker, and the use of such fusion proteins in the treatment of diabetes. The fusion protein of the present invention has an extended time action profile and is useful for providing basal glucose control for an extended period of time.
    Type: Grant
    Filed: June 5, 2020
    Date of Patent: February 22, 2022
    Assignee: Eli Lilly and Company
    Inventors: David Bruce Baldwin, John Michael Beals, Jonathan Wesley Day, Craig Duane Dickinson, Andrew Ihor Korytko, Gregory Alan Lazar
  • Patent number: 11254721
    Abstract: The present invention relates to compounds having activity at the human glucose-dependent insulinotropic polypeptide (GIP) receptor. The present invention also relates to compounds having an extended duration of action at the GIP receptor. Such compounds may be useful in the treatment of diabetes, including type 2 diabetes mellitus (“T2DM”). Also, the compounds may be useful in the treatment of obesity.
    Type: Grant
    Filed: July 29, 2020
    Date of Patent: February 22, 2022
    Assignee: Eli Lilly and Company
    Inventors: Jorge Alsina-Fernandez, Andrea Renee Geiser, Lili Guo, Samantha Grace Lyons Keyser, John Lee, Hongchang Qu, William Christopher Roell
  • Publication number: 20220048982
    Abstract: The present invention relates to anti-alpha-synuclein antibodies, and uses thereof for treating diseases such as Parkinson's disease.
    Type: Application
    Filed: December 9, 2019
    Publication date: February 17, 2022
    Applicant: Eli Lilly and Company
    Inventors: Johnny Eugene CROY, Mansuo Lu HAYASHI, Jirong LU, Bo MA, Ying TANG
  • Patent number: 11242383
    Abstract: Angiopoietin-like protein (ANGPTL)3/8 complexes and antibodies are disclosed, where the antibodies bind to and thereby neutralize ANGPTL3/8 complexes. Pharmaceutical compositions also are disclosed that include one or more anti-ANGPTL3/8 complex antibodies herein in a pharmaceutically acceptable carrier. Methods of making and using the same also are disclosed, especially for increase lipoprotein lipase activity and lowering triglycerides. In this manner, the compounds and compositions may be used in treating lipid metabolism-related and glucose metabolism-related diseases and disorders.
    Type: Grant
    Filed: December 13, 2019
    Date of Patent: February 8, 2022
    Assignee: Eli Lilly and Company
    Inventors: Qing Chai, Jonathan Wesley Day, Robert John Konrad, Yuewei Qian, Oliver Schroeder, Robert William Siegel
  • Patent number: RE49091
    Type: Grant
    Filed: December 5, 2018
    Date of Patent: June 7, 2022
    Assignee: Eli Lilly and Company
    Inventors: Jesse Arnold Fourt, Thomas Dieter Christian Overthun, Judy Guo, Thomas Gaëtan Thibault Brisebras